Navigation Links
Pandemic vaccination did not increase risk of fetal death
Date:1/17/2013

With the rapid progression of molecular biology and genetics, and the subsequent emergence of many new targets, emerging targets & therapeutics provides new opportunities for the prevention and treatment of several major disease systems. The 4th Cancer Targets & Therapeutics Conference, taking place on February 25-26, 2013 in Las Vegas, NV will continue to be a premier event for translational researchers, preclinical scientists and managers, and those carrying out early phase clinical trials, working to identify and exploit advances in the field in order to deliver products with a meaningful clinical impact. Both cutting-edge researchers and those who guide its commercial development will be on-hand to share their knowledge and insights as to how therapeutic cancer targets are identified, and how this research translates into meaningful therapeutics that benefit patients living with cancer.

Attendees will learn about:

  • Important progress in key aspects of antibody, vaccine, and cell-based therapies being developed and evaluated in clinical trials for the immunotherapy of cancer

  • How cellular pathways of protein processing and pivotal cell-death pathways are being targeted by new Therapies New therapeutic targets in epigenetic and newly described metabolic pathways that serve as new pathways for drug discovery

  • Advances in targeting angiogenesis

  • Important new animal models for target validation

  • New approaches to drug-conjugates and to dose evaluation for effective therapy

Preliminary Sessions for 2013 Agenda:

  • Novel Kinase Inhibitors & Beyond the Kinome

  • Functional Genomics & Future Cancer targets

  • Novel Antibody-based Modalities

  • Progress in Cancer Immunotherapy

  • Cancer Stem Cells, Metabolism, Cancer Epigenetics

  • Novel Advances & Technologies in Oncology


'/>"/>

Contact: Press Officer
47-210-78300
Norwegian Institute of Public Health
Source:Eurekalert

Page: 1

Related biology news :

1. Improving equine health: Research studies vaccinations to protect newborn foals
2. The effect of treatment with antibiotics and vaccination against Q fever in sheep
3. Teens susceptible to hepatitis B infection despite vaccination as infants
4. Increase in Arctic shipping poses risk to marine mammals
5. Columbia Engineering and Penn researchers increase speed of single-molecule measurements
6. Fertilizer use responsible for increase in nitrous oxide in atmosphere
7. NIST/UMass study finds evidence nanoparticles may increase plant DNA damage
8. Study finds soda consumption increases overall stroke risk
9. Scientists have discovered genes that increase the risk of osteoporosis and fractures
10. Family history of liver cancer increases risk of developing the disease
11. Research shows how PCBs promote dendrite growth, may increase autism risk
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/12/2016)... , May 12, 2016 WearablesResearch.com ... just published the overview results from the Q1 wave ... the recent wave was consumers, receptivity to a program ... data with a health insurance company. "We ... to share," says Michael LaColla , CEO of ...
(Date:5/3/2016)... 3, 2016  Neurotechnology, a provider of high-precision ... Automated Biometric Identification System (ABIS) , a complete ... MegaMatcher ABIS can process multiple complex biometric transactions ... of fingerprint, face or iris biometrics. It leverages ... and MegaMatcher Accelerator , which have been ...
(Date:4/28/2016)... -- First quarter 2016:   , Revenues ... first quarter of 2015 The gross margin was 49% ... and the operating margin was 40% (-13) Earnings per ... from operations was SEK 249.9 M (21.2) , Outlook ... 7,000-8,500 M. The operating margin for 2016 is estimated ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... 27, 2016 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ("Biorem" or ... its major shareholders, Clean Technology Fund I, LP and ... based venture capital funds which together hold ... a fully diluted, as converted basis), that they have ... entire equity holdings in Biorem to TUS Holdings Co. ...
(Date:6/27/2016)... ... 2016 , ... Parallel 6 , the leading software as a service ... Virtual Patient Encounter CONSULT module which enables both audio and video telemedicine communication ... , Using the CONSULT module, patients and physicians can schedule a face to face ...
(Date:6/27/2016)...  Liquid Biotech USA , ... Sponsored Research Agreement with The University of Pennsylvania ... cancer patients.  The funding will be used to ... clinical outcomes in cancer patients undergoing a variety ... employed to support the design of a therapeutic, ...
(Date:6/24/2016)... 24, 2016 Epic Sciences unveiled a ... susceptible to PARP inhibitors by targeting homologous recombination ... The new test has already been incorporated into ... cancer types. Over 230 clinical trials ... pathways, including PARP, ATM, ATR, DNA-PK and WEE-1. ...
Breaking Biology Technology: